Use of infection biomarkers in the emergency department

Ozger, H.Selcuk; ŞENOL, ESİN

doi:10.4103/2452-2473.357347

Use of infection biomarkers in the emergency department

Hasan Selçuk ÖZGER, (Gazi Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji, Ankara, Türkiye)

Esin ŞENOL (Gazi Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji, Ankara, Türkiye)

Turkish journal of emergency medicine (Online)

3 0

Yıl: 2022 Cilt: 22 Sayı: 4 Sayfa Aralığı: 169 - 176 Metin Dili: İngilizce DOI: 10.4103/2452-2473.357347 İndeks Tarihi: 11-10-2022

Use of infection biomarkers in the emergency department

Öz:

he use of infection biomarkers in the emergency department is discussed in terms of their possible contributions to diagnostic-prognostic uncertainties, appropriate antibiotic treatments, and triage and follow-up planning. Procalcitonin (PCT), C-reactive protein (CRP), proadrenomedullin (proADM), and presepsin are among the most discussed infection biomarkers for use in the emergency department. Due to the variable sensitivity results and cutoff values, there are insufficient data to recommend the widespread use of CRP and procalcitonin (PCT) for the diagnosis and prognosis of infection in the emergency department. However, these biomarkers can be used for appropriate antibiotic use in selected infection groups, such as community-acquired pneumonia, especially to reduce unnecessary antibiotic prescribing. With its prognostic superiority over other biomarkers and its contribution to prognostic score systems in community-acquired pneumonia (CAP), proADM can be used to predict hospitalization, preferably within the scope of clinical studies. Although presepsin has been shown to have some advantages over other biomarkers to rule out sepsis, there are insufficient data for its clinical use in the emergency department.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Schuetz P, Aujesky D, Müller C, Müller B. Biomarker guided personalised emergency medicine for all – Hope for another hype? Swiss Med Wkly 2015;145:w14079.
2. Hausfater P. Biomarkers and infection in the emergency unit. Med Mal Infect 2014;44:139 45.
3. CDC, National Hospital Ambulatory Medical Care Survey; 2018 Emergency Department Summary Tables. Available from: https://www.cdc.gov/nchs/data/nhamcs/web_ tables/2018 ed web Tables 508.pdf, 2018. 04.10.2022.
4. Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res 2000;49 Suppl 1:S57 61.
5. Barichello T, Generoso JS, Singer M, Dal Pizzol F. Biomarkers for sepsis: More than just fever and leukocytosis – A narrative review. Crit Care 2022;26:14.
6. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79:1605 8.
7. Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med 2013;28:285 91.
8. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations. Crit Care Med 2008;36:941 52.
9. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990 2017: Analysis for the global burden of disease study. Lancet 2020;395:200 11.
10. Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019 – Results from a systematic review and meta analysis. Crit Care 2020;24:239.
11. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Crit Care Med 2021;49:e1063 143.
12. Cong S, Ma T, Di X, Tian C, Zhao M, Wang K. Diagnostic value of neutrophil CD64, procalcitonin, and interleukin 6 in sepsis: A meta analysis. BMC Infect Dis 2021;21:384.
13. van der Does Y, Limper M, Jie KE, Schuit SC, Jansen H, Pernot N, et al. Procalcitonin guided antibiotic therapy in patients with fever in a general emergency department population: A multicentre non inferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect 2018;24:1282 9.
14. Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteraemia: A systematic review and meta analysis. Clin Microbiol Infect 2015;21:474 81.
15. Jia CM, Feng SY, Li Y, Cao ZX, Wu CP, Zhai YZ, et al. Procalcitonin for predicting catheter associated bloodstream infection: A meta analysis. Medicine (Baltimore) 2019;98:e18546.
16. Yan ST, Sun LC, Jia HB, Gao W, Yang JP, Zhang GQ. Procalcitonin levels in bloodstream infections caused by different sources and species of bacteria. Am J Emerg Med 2017;35:579 83.
17. Self WH, Balk RA, Grijalva CG, Williams DJ, Zhu Y, Anderson EJ, et al. Procalcitonin as a marker of etiology in adults hospitalized with community acquired pneumonia. Clin Infect Dis 2017;65:183 90.
18. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to distinguish viral from bacterial pneumonia: A systematic review and meta analysis. Clin Infect Dis 2020;70:538 42.
19. Vikse J, Henry BM, Roy J, Ramakrishnan PK, Tomaszewski KA, Walocha JA. The role of serum procalcitonin in the diagnosis of bacterial meningitis in adults: A systematic review and meta analysis. Int J Infect Dis 2015;38:68 76.
20. Wei TT, Hu ZD, Qin BD, Ma N, Tang QQ, Wang LL, et al. Diagnostic accuracy of procalcitonin in bacterial meningitis versus nonbacterial meningitis: A systematic review and meta analysis. Medicine (Baltimore) 2016;95:e3079.
21. Sager R, Wirz Y, Amin D, Amin A, Hausfater P, Huber A, et al. Are admission procalcitonin levels universal mortality predictors across different medical emergency patient populations? results from the multi national, prospective, observational TRIAGE study. Clin Chem Lab Med 2017;55:1873 80.
22. Liu D, Su LX, Guan W, Xiao K, Xie LX. Prognostic value of procalcitonin in pneumonia: A systematic review and meta analysis. Respirology 2016;21:280 8.
23. Arora S, Singh P, Singh PM, Trikha A. Procalcitonin levels in survivors and nonsurvivors of sepsis: Systematic review and meta analysis. Shock 2015;43:212 21.
24. Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 2013;17:R115.
25. Schuetz P, Wirz Y, Sager R, Christ Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017;10:CD007498.
26. Mathioudakis AG, Chatzimavridou Grigoriadou V, Corlateanu A, Vestbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: A meta analysis. Eur Respir Rev 2017;26:160073.
27. Doğan NÖ, Varol Y, Köktürk N, Aksay E, Alpaydın AÖ, Çorbacıoğlu ŞK, et al. 2021 Guideline for the management of COPD exacerbations: Emergency medicine association of turkey (EMAT)/turkish thoracic society (TTS) clinical practice guideline task force. Turk J Emerg Med 2021;21:137 76.
28. Huang DT, Yealy DM, Filbin MR, Brown AM, Chang CH, Doi Y, et al. Procalcitonin guided use of antibiotics for lower respiratory tract ınfection. N Engl J Med 2018;379:236 49.
29. Andriolo BN, Andriolo RB, Salomão R, Atallah ÁN. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev 2017;1:CD010959.
30. Clyne B, Olshaker JS. The C reactive protein. J Emerg Med 1999;17:1019 25.
31. Tan M, Lu Y, Jiang H, Zhang L. The diagnostic accuracy of procalcitonin and C reactive protein for sepsis: A systematic review and meta analysis. J Cell Biochem 2019;120:5852 9.
32. Ebell MH, Bentivegna M, Cai X, Hulme C, Kearney M. Accuracy of biomarkers for the diagnosis of adult community acquired pneumonia: A meta analysis. Acad Emerg Med 2020;27:195 206.
33. Gbinigie OA, Onakpoya IJ, Richards GC, Spencer EA, Koshiaris C, Bobrovitz N, et al. Biomarkers for diagnosing serious bacterial infections in older outpatients: A systematic review. BMC Geriatr 2019;19:190.
34. Levinson T, Tamir N, Shenhar Tsarfaty S, Paran Y, Zeltzer D, Shapira I, et al. The potential benefit of a second C reactive protein measurement in patients with gram negative bacteraemia presenting to the emergency medicine department. Biomarkers 2020;25:533 8.
35. Coster D, Wasserman A, Fisher E, Rogowski O, Zeltser D, Shapira I, et al. Using the kinetics of C reactive protein response to improve the differential diagnosis between acute bacterial and viral infections. Infection 2020;48:241 8.
36. Simon L, Gauvin F, Amre DK, Saint Louis P, Lacroix J. Serum procalcitonin and C reactive protein levels as markers of bacterial infection: A systematic review and meta analysis. Clin Infect Dis 2004;39:206 17.
37. Steuerman Y, Wasserman A, Zeltser D, Shapira I, Trotzky D, Halpern P, et al. Anemia measurements to distinguish between viral and bacterial infections in the emergency department. Eur J Clin Microbiol Infect Dis 2019;38:2331 9.
38. Tamayose M, Fujita J, Parrott G, Miyagi K, Maeshiro T, Hirata T, et al. Correlations between extent of X ray infiltration and levels of serum C reactive protein in adult non severe community acquired pneumonia. J Infect Chemother 2015;21:456 63.
39. Huang D, He D, Gong L, Wang W, Yang L, Zhang Z, et al. Clinical characteristics and risk factors associated with mortality in patients with severe community acquired pneumonia and type 2 diabetes mellitus. Crit Care 2021;25:419.
40. Rachina S, Bobylev A, Lazarev P, Mladov V, Carrouel F, Avdeev S, et al. Biomarker value in the diagnosis of community acquired pneumonia with concomitant chronic heart failure. J Clin Med 2021;10:4570.
41. Stalenhoef JE, van Nieuwkoop C, Wilson DC, van der Starre WE, van der Reijden TJK, Delfos NM, et al. Procalcitonin, mid regional proadrenomedullin and C reactive protein in predicting treatment outcome in community acquired febrile urinary tract infection. BMC Infect Dis 2019;19:161.
42. Myoung JY, Hong JY, Lee DH, Lee CA, Park SH, Kim DH, et al. Factors for return to emergency department and hospitalization in elderly urinary tract infection patients. Am J Emerg Med 2021;50:283 8.
43. Cochon L, Ovalle A, Nicolás JM, Baez AA. Acute care diagnostic collaboration: Bayesian modeling comparative diagnostic assessment of lactate, procalcitonin and CRP in risk stratified population by Mortality in ED (MEDS) score. Am J Emerg Med 2017;35:564 8.
44. Kutz A, Grolimund E, Christ Crain M, Thomann R, Falconnier C, Hoess C, et al. Pre analytic factors and initial biomarker levels in community acquired pneumonia patients. BMC Anesthesiol 2014;14:102.
45. Méndez R, Menéndez R, Cillóniz C, Amara Elori I, Amaro R, González P, et al. Initial ınflammatory profile in community acquired pneumonia depends on time since onset of symptoms. Am J Respir Crit Care Med 2018;198:370 8.
46. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community acquired pneumonia. An official clinical practice guideline of the American thoracic society and ınfectious diseases society of America. Am J Respir Crit Care Med 2019;200:e45 67.
47. AL. GBE. EAU Guidelines on Urological Infections UROLOGICAL INFECTIONS LIMITED UPDATE MARCH 2020: 2020.
48. Lim DW, Htun HL, Ong LS, Guo H, Chow A. Systematic review of determinants influencing antibiotic prescribing for uncomplicated acute respiratory tract infections in adult patients at the emergency department. Infect Control Hosp Epidemiol 2022;43:366 75.
49. Althaus T, Greer RC, Swe MM, Cohen J, Tun NN, Heaton J, et al. Effect of point of care C reactive protein testing on antibiotic prescription in febrile patients attending primary care in Thailand and Myanmar: An open label, randomised, controlled trial. Lancet Glob Health 2019;7:e119 31.
50. Martínez González NA, Keizer E, Plate A, Coenen S, Valeri F, Verbakel JY, et al. Point of care C reactive protein testing to reduce antibiotic prescribing for respiratory tract ınfections in primary care: Systematic review and meta analysis of randomised controlled trials. Antibiotics (Basel) 2020;9:610.
51. Butler CC, Gillespie D, White P, Bates J, Lowe R, Thomas Jones E, et al. C reactive protein testing to guide antibiotic prescribing for COPD exacerbations. N Engl J Med 2019;381:111 20.
52. Prins HJ, Duijkers R, van der Valk P, Schoorl M, Daniels JM, van der Werf TS, et al. CRP guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J 2019;53(5):1802014.
53. Liu D, Xie L, Zhao H, Liu X, Cao J. Prognostic value of mid regional pro adrenomedullin (MR proADM) in patients with community acquired pneumonia: A systematic review and meta analysis. BMC Infect Dis 2016;16:232.
54. Cavallazzi R, El Kersh K, Abu Atherah E, Singh S, Loke YK, Wiemken T, et al. Midregional proadrenomedullin for prognosis in community acquired pneumonia: A systematic review. Respir Med 2014;108:1569 80.
55. Elke G, Bloos F, Wilson DC, Brunkhorst FM, Briegel J, Reinhart K, et al. The use of mid regional proadrenomedullin to identify disease severity and treatment response to sepsis – A secondary analysis of a large randomised controlled trial. Crit Care 2018;22:79.
56. Gonzalez Del Castillo J, Clemente Callejo C, Llopis F, Irimia A, Oltra Hostalet F, Rechner C, et al. Midregional proadrenomedullin safely reduces hospitalization in a low severity cohort with infections in the ED: A randomized controlled multi centre interventional pilot study. Eur J Intern Med 2021;88:104 13.
57. Stalenhoef JE, van Nieuwkoop C, Wilson DC, van der Starre WE, Delfos NM, Leyten EM, et al. Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary tract infection. J Infect 2018;77:18 24.
58. Yoon SH, Kim EH, Kim HY, Ahn JG. Presepsin as a diagnostic marker of sepsis in children and adolescents: A systemic review and meta analysis. BMC Infect Dis 2019;19:760.
59. Hayashida K, Kondo Y, Hara Y, Aihara M, Yamakawa K. Head to head comparison of procalcitonin and presepsin for the diagnosis of sepsis in critically ill adult patients: A protocol for a systematic review and meta analysis. BMJ Open 2017;7:e014305.
60. Lee S, Song J, Park DW, Seok H, Ahn S, Kim J, et al. Diagnostic and prognostic value of presepsin and procalcitonin in non infectious organ failure, sepsis, and septic shock: A prospective observational study according to the sepsis 3 definitions. BMC Infect Dis 2022;22:8.
61. Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: Data from the albumin ıtalian outcome sepsis trial. Crit Care 2014;18:R6.
62. Yang HS, Hur M, Yi A, Kim H, Lee S, Kim SN. Prognostic value of presepsin in adult patients with sepsis: Systematic review and meta analysis. PLoS One 2018;13:e0191486.
63. Imai Y, Taniguchi K, Iida R, Nitta M, Uchiyma K, Takasu A. Diagnostic accuracy of presepsin in predicting bacteraemia in elderly patients admitted to the emergency department: Prospective study in Japan. BMJ Open 2019;9:e030421.
64. Ham JY, Song KE. A prospective study of presepsin as an ındicator of the severity of community acquired pneumonia in emergency departments: Comparison with pneumonia severity ındex and CURB 65 scores. Lab Med 2019;50:364 9.

APA	Ozger H, ŞENOL E (2022). Use of infection biomarkers in the emergency department. , 169 - 176. 10.4103/2452-2473.357347
Chicago	Ozger H.Selcuk,ŞENOL ESİN Use of infection biomarkers in the emergency department. (2022): 169 - 176. 10.4103/2452-2473.357347
MLA	Ozger H.Selcuk,ŞENOL ESİN Use of infection biomarkers in the emergency department. , 2022, ss.169 - 176. 10.4103/2452-2473.357347
AMA	Ozger H,ŞENOL E Use of infection biomarkers in the emergency department. . 2022; 169 - 176. 10.4103/2452-2473.357347
Vancouver	Ozger H,ŞENOL E Use of infection biomarkers in the emergency department. . 2022; 169 - 176. 10.4103/2452-2473.357347
IEEE	Ozger H,ŞENOL E "Use of infection biomarkers in the emergency department." , ss.169 - 176, 2022. 10.4103/2452-2473.357347
ISNAD	Ozger, H.Selcuk - ŞENOL, ESİN. "Use of infection biomarkers in the emergency department". (2022), 169-176. https://doi.org/10.4103/2452-2473.357347

APA	Ozger H, ŞENOL E (2022). Use of infection biomarkers in the emergency department. Turkish journal of emergency medicine (Online), 22(4), 169 - 176. 10.4103/2452-2473.357347
Chicago	Ozger H.Selcuk,ŞENOL ESİN Use of infection biomarkers in the emergency department. Turkish journal of emergency medicine (Online) 22, no.4 (2022): 169 - 176. 10.4103/2452-2473.357347
MLA	Ozger H.Selcuk,ŞENOL ESİN Use of infection biomarkers in the emergency department. Turkish journal of emergency medicine (Online), vol.22, no.4, 2022, ss.169 - 176. 10.4103/2452-2473.357347
AMA	Ozger H,ŞENOL E Use of infection biomarkers in the emergency department. Turkish journal of emergency medicine (Online). 2022; 22(4): 169 - 176. 10.4103/2452-2473.357347
Vancouver	Ozger H,ŞENOL E Use of infection biomarkers in the emergency department. Turkish journal of emergency medicine (Online). 2022; 22(4): 169 - 176. 10.4103/2452-2473.357347
IEEE	Ozger H,ŞENOL E "Use of infection biomarkers in the emergency department." Turkish journal of emergency medicine (Online), 22, ss.169 - 176, 2022. 10.4103/2452-2473.357347
ISNAD	Ozger, H.Selcuk - ŞENOL, ESİN. "Use of infection biomarkers in the emergency department". Turkish journal of emergency medicine (Online) 22/4 (2022), 169-176. https://doi.org/10.4103/2452-2473.357347